ERBB2 and neoplasm: There are several hypotheses for low HER2 stability (e.g., genetic drift and clonal evolution during tumor progression, intratumoral heterogeneity, and the selective effect of administered therapies) leading to the enrichment of HER2 expression [41,60,61,62,63,64,65,66].